Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Sangamo Biosciences Inc (SGMO)  
$0.52 0.04 (6.83%) as of 4:30 Wed 4/10


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 140,990,000
Market Cap: 73.88(M)
Last Volume: 2,041,307 Avg Vol: 1,748,484
52 Week Range: $0.2971 - $1.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 6,000,000 6,500,000
Total Sell Value $0 $0 $3,000,000 $5,657,240
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 3
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 539
  Page 19 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gregory Philip D SVP of Research & CSO   •       –      –    2014-12-01 4 OE $3.45 $77,000 D/D 15,000 124,347     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-11-17 4 AS $11.23 $280,843 D/D (25,000) 295,000     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-11-17 4 OE $4.11 $102,750 D/D 25,000 320,000     -
   Larson John William Director   –       •      –    2014-11-12 4 AS $12.00 $120,007 D/D (10,000) 214,660     -
   Larson John William Director   –       •      –    2014-11-12 4 OE $4.10 $41,000 D/D 10,000 224,660     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2014-11-10 4 AS $11.37 $22,748 D/D (2,000) 213,353     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-11-05 4 AS $11.35 $170,258 D/D (15,000) 97,856     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-11-05 4 OE $4.11 $83,877 D/D 15,000 112,856     -
   Gregory Philip D SVP of Research & CSO   •       –      –    2014-11-03 4 AS $11.91 $178,704 D/D (15,000) 109,347     -
   Gregory Philip D SVP of Research & CSO   •       –      –    2014-11-03 4 OE $3.45 $79,240 D/D 15,000 124,347     -
   Larson John William Director   –       •      –    2014-10-28 4 AS $12.02 $120,153 D/D (10,000) 214,660     -
   Larson John William Director   –       •      –    2014-10-28 4 OE $7.28 $72,800 D/D 10,000 224,660     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-10-15 4 AS $10.49 $262,365 D/D (25,000) 295,000     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-10-15 4 OE $4.11 $102,750 D/D 25,000 320,000     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2014-10-10 4 AS $10.10 $20,200 D/D (2,000) 214,347     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-10-06 4 AS $10.72 $160,865 D/D (15,000) 96,579     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-10-06 4 OE $4.11 $61,650 D/D 15,000 111,579     -
   Gregory Philip D SVP of Research & CSO   •       –      –    2014-10-01 4 AS $10.80 $162,029 D/D (15,000) 109,347     -
   Gregory Philip D SVP of Research & CSO   •       –      –    2014-10-01 4 OE $3.45 $84,840 D/D 15,000 124,347     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-09-15 4 AS $12.14 $303,383 D/D (25,000) 295,000     -
   Lanphier Edward O Ii President & CEO   •       •      –    2014-09-15 4 OE $4.11 $102,750 D/D 25,000 320,000     -
   Wolff Henry Ward Exec VP & CFO   •       –      –    2014-09-10 4 AS $12.31 $24,620 D/D (2,000) 216,347     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-09-05 4 AS $12.20 $183,072 D/D (15,000) 96,579     -
   Ando Dale G VP, Therapeutic Dev. & CMO   •       –      –    2014-09-05 4 OE $4.11 $61,650 D/D 15,000 111,579     -
   Larson John William Director   –       •      –    2014-09-04 4 AS $12.81 $128,082 D/D (10,000) 218,160     -
  539 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 19 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us